Prosensa Announces Extraordinary Shareholders Meeting to Appoint Dr. Georges Gemayel
Leiden, The Netherlands, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch
biopharmaceutical company focusing on rare diseases with a high
unmet medical need, today announced that an Extraordinary General
Meeting of Shareholders will be held on January 23rd,
2014 at 14:00 hrs. CET at the offices of Prosensa Holding N.V.,
J.H. Oortweg 21, 2333 CH Leiden, The Netherlands.
The purpose of the meeting is to appoint Dr.
Georges Gemayel, PhD as a new Supervisory Board member.
Dr. Georges Gemayel currently serves on several
boards, including those of NPS Pharmaceuticals, Orphazyme, Vascular
Magnetics and EpiTherapeutics. Previous board memberships include
Executive Chairman of the Board at FoldRx, a neurodegenerative
disease company that is now a wholly owned subsidiary of Pfizer and
a board director at Adolor Corporation, which has since been
acquired by Cubist Pharmaceuticals. Dr. Georges Gemayel's
operational experience is extensive, having served as President
& CEO of Waltham based Altus Pharmaceuticals and most notably
as Executive Vice President of Genzyme Corporation from 2003 to
2008, among others.
"Georges will bring unparalleled industry
experience in the rare disease space and strategic corporate
leadership to our board at a pivotal time for the company," said
David Mott, Chairman of the Supervisory Board of Prosensa.
Hans Schikan, Chief Executive Officer of
Prosensa, added, "We welcome Georges as an instrumental addition to
our Supervisory Board. Georges' expertise in rare diseases
will be of tremendous value in building our company and developing
therapies for rare diseases with a high unmet medical need. His
unique experience gleaned from his leadership at Genzyme will be
invaluable as we continue to develop our pipeline of DMD
Dr. Georges Gemayel also added, "Prosensa has
established a world-class team with exceptional leadership and I am
pleased to have the opportunity to contribute to the company's
growth in a meaningful way. It will be an honor to become part of a
patient-centric rare disease organization which has been a pioneer
in the journey of helping boys with Duchenne muscular dystrophy and
The notice and agenda of the Extraordinary
General Meeting are available on the "Investors & Media"
section of Prosensa's website at www.prosensa.com. The notice of the
Extraordinary General Meeting (which has been filed with the SEC on
a Form 6-K) is also available on the SEC's website at www.sec.gov.
Notes to editors
About Prosensa Holding N.V.
Prosensa (NASDAQ: RNA) is a Dutch biotechnology
company engaged in the discovery and development of RNA-modulating
therapeutics for the treatment of genetic disorders. Its primary
focus is on rare neuromuscular and neurodegenerative disorders with
a large unmet medical need, including Duchenne muscular dystrophy
(DMD), myotonic dystrophy and Huntington's disease.
Prosensa's current portfolio includes six
compounds for the treatment of DMD, all of which have received
orphan drug status in the United States and the European Union. The
compounds use an innovative technique called exon-skipping to
provide a personalized medicine approach to treat different
populations of DMD patients. www.prosensa.com
CONTACT: Prosensa Holding N.V.
Celia Economides, Director IR & Corporate Communications
Phone: +1 917 975 1983
Source: Prosensa Holding N.V.
News Provided by Acquire Media
Close window | Back to top